Genome-wide association study reveals loci with sex-specific effects on plasma bile acids

- Arianna Landini^{1,2}, Dariush Ghasemi-Semeskandeh^{3,4}, Åsa Johansson⁵, Shahzad Ahmad⁶, 4
- Gerhard Liebisch⁷, Carsten Gnewuch⁷, Regeneron Genetics Center⁸, Gannie Tzoneva⁸, Alan 5
- R. Shuldiner⁸, Andrew A. Hicks³, Peter Pramstaller³, Cristian Pattaro³, Harry Campbell², Ozren 6
- Polašek^{9,10}, Nicola Pirastu¹¹, Caroline Hayward¹, Mohsen Ghanbari⁶, Ulf Gyllensten⁵, 7
- Christian Fuchsberger³, James F. Wilson*^{1,2} & Lucija Klarić*¹ 8
- 10 1 MRC Human Genetics Unit, Institute for Genetics and Cancer, University of Edinburgh,
- 11 Edinburgh, United Kingdom
- 2 Centre for Global Health Research, Usher Institute, University of Edinburgh, Edinburgh, 12
- 13 United Kingdom

1

2 3

9

- 14 3 Institute for Biomedicine, Eurac Research, Affiliated Institute of the University of Lübeck,
- 15 Bolzano, Italy
- 16 4 Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands
- 17 5 Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala
- 18 University, Uppsala, Sweden
- 19 6 Department of Epidemiology, Erasmus MC University Medical Center, Rotterdam, The
- 20 Netherlands

27

- 21 7 Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Regensburg,
- 22 Regensburg, Germany
- 23 8 Regeneron Genetics Center, Tarrytown, NY, USA
- 24 9 Department of Public Health, School of Medicine, University of Split, Split, Croatia
- 25 10 Algebra University College, Zagreb, Croatia
- 26 11 Genomics Research Centre, Human Technopole, Milan, Italy
- 28 * Authors contributed equally.
- 29 Correspondence to: J.F.W (jim.wilson@ed.ac.uk) or L.K. (lucija.klaric@ed.ac.uk)

Abstract

30

31

32

33 34

35

36 37

38

39

40

41

42

43 44

45 46

47

Bile acids are essential for food digestion and nutrient absorption, but also act as signalling molecules involved in hepatobiliary diseases, gastrointestinal disorders and carcinogenesis. While many studies have focused on the genetic determinants of blood metabolites, research focusing specifically on genetic regulation of bile acids in the general population is currently lacking. Here we investigate the genetic architecture of primary and secondary bile acids in blood plasma, reporting associations with both common and rare variants. By performing genome-wide association analysis (GWAS) of plasma blood levels of 18 bile acids (N = 4923) we identify two significantly associated loci, a common variant mapping to SLCO1B1 (encoding a liver bilirubin and drug transporter) and a rare variant in *PRKG1* (encoding soluble cyclic GMP-dependent protein kinase). For these loci, in the sex-stratified GWAS ($N_{\odot}^{\uparrow} = 820$, N = 1088), we observe sex-specific effects (SLCO1B1 $\beta = -0.51$, $P = 2.30 \times 10^{-13}$, $\beta = -0.51$ 0.3, $P = 9.90 \times 10^{-07}$; $PRKG1 \beta = -0.18$, $P = 1.80 \times 10^{-01}$, $\beta = -0.79$, $P = 8.30 \times 10^{-11}$), corroborating the contribution of sex to bile acid variability. Using gene-based aggregate tests and whole exome sequencing, we identify rare pLoF and missense variants potentially associated with bile acid levels in 3 genes (OR1G1, SART1 and SORCS2), some of which have been linked with liver diseases.

Introduction

48

49

50

51 52

53 54

55

56

57

58

59 60

61 62

63

64 65

66

67 68

69

70 71

72

73

74

75 76

77

78

79 80

81

82

83

Bile acids (BAs) are synthesised from cholesterol in the liver and subsequently stored in the gallbladder. After ingestion of food, BAs are secreted into the small intestine, where they contribute to the digestion of lipid-soluble nutrients¹. Approximately 95% of BAs are then reabsorbed by the intestinal epithelium and transported back to the liver via the portal vein - a process termed "enterohepatic circulation"². Primary bile acids in humans consists of cholic acid (CA), chenodeoxycholic acid (CDCA), and their taurine- or glycine-bound derivatives (TCA and TCDCA, GCA and GCDCA). Once secreted in the lower gastrointestinal tract, primary BAs are heavily modified by the gut microbiota to produce a broad range of secondary BAs, with deoxycholic acid (DCA), a CA derivative, and lithocholic acid (LCA), a CDCA derivative, being the most prevalent². Bile acids also act as hormone-like signalling molecules. serving as ligands to nuclear (hormone) receptors. Through activation of these diverse signalling pathways, BAs control not only their own transport and metabolism, but also lipid and glucose metabolism, and innate and adaptive immunity³. Bile acids are thus involved in regulating several physiological systems, such as fat digestion, cholesterol metabolism, vitamin absorption, and liver function⁴. In addition, given their role in coordinating bile homeostasis, biliary physiology and gastrointestinal functions, impaired signalling of BAs is associated with development of hepatobiliary diseases, such as cholestatic liver disorders, cholesterol gallstone disease and other gallbladder-related conditions⁵, and of inflammatory bowel disease⁶. Further, bile acids have been implicated in carcinogenesis - specifically oesophageal, gastric, hepatocellular, pancreatic, colorectal, breast, prostate and ovarian cancer - both as procarcinogenic agents and tumour suppressors⁷. Thanks to their role as signalling molecules, BAs have been considered as possible targets for the treatment of metabolic syndrome and various metabolic diseases⁸. Further, BAs are able to facilitate and promote drug permeation through biological membranes, making them of general interest for drug formulation and delivery⁹.

While many studies have focused on the genetic determinants of blood metabolites 10-15, research focusing specifically on bile acids in a large sample from the general population is currently lacking. Here we investigate the genetic architecture of primary and secondary BAs, reporting associations with both common and low-frequency/rare variants. First, we performed a genome-wide association meta-analysis (GWAMA) of plasma blood levels of 18 BA traits (N=4923). For a subset of this sample (female N=1088, male N=820), we perform sex-stratified GWAMA, to describe sex-specific genetic contributions to BA variability. We then explore whether complex traits or diseases have a role in influencing BA variability by using Mendelian Randomisation. We finally employ multiple gene-based aggregation tests to investigate rare (MAF < 5%) predicted loss of function (pLoF) and missense variants from whole exome sequencing affecting the 18 BA traits in a subset of our cohorts (N=1006).

Results

84 85 86

87 88

89 90

91 92

93

94

95

96

97

98 99

100

101

102

103

104 105

106

107

108

109 110

Loci associated with serum levels of bile acids

To investigate the genetic control of bile acids, we performed a GWAS meta-analysis on five cohorts of European descent (N = 4923), studying the associations of blood plasma levels of 18 primary and secondary bile acid traits with HRC-imputed genotypes/whole exome sequence data. Based on the number of below limit-of-detection (LOD) measurements, BAs were analysed either as quantitative or binary traits (Supplementary Table 1). In addition, two analysis approaches were carried out in parallel for quantitative traits: in one case, <LOD values were considered as missing, in the other case, they were imputed (Methods). An additive linear model was assumed for each bile acid trait, followed by fixed-effect inverse-variance meta-analysis. Overall, we identified 2 loci that passed the significance threshold (pvalue < 3.57 x 10⁻⁹, Bonferroni adjusted for the number of independent bile acid traits) (Figure 1), near the SLCO1B1 and PRKG1 genes. The most strongly associated locus (p=1.14) x 10⁻¹⁶), on chromosome 12 near *SLCO1B1*, showed consistent directionality across 4 of the 5 populations (Table 1), with the effect allele T of the sentinel SNP, rs4149056, associated with decreased serum levels of GDCA (quantitative). In the same locus, we found GLCA and the imputed GDCA trait to be significantly associated with the rs73079476 variant (Supplementary Table 2), in high linkage disequilibrium with the sentinel SNP, rs4149056 ($r^2 = 0.97$). On the other hand, rs146800892, the sentinel SNP on chromosome 10 near PRKG1, has a minor allele frequency (MAF) lower than 1% in any cohort but CROATIA-Vis and might thus represent a cohort-specific association with GCA (Supplementary Table 2).




Figure 1. Summary Manhattan plot pooling together meta-analysis results obtained across 18 bile acid traits. The pooling was performed by selecting the lowest p value (y-axis) from the 18 bile acids for every genomic position (x-axis). The Bonferroni-corrected genome-

- wide significance threshold (horizontal red line) corresponds to 3.57×10^{-9} . For simplicity, 111
- SNPs with p value $> 1 \times 10^{-3}$ are not plotted. P values are derived from the two-sided Wald test 112
- with one degree of freedom. 113

114 Table 1: Loci genome-wide significantly associated with at least one of the 18 bile acid traits in all samples and sex-stratified GWAMA

All samples										
Locus	Gene	SNP	EA	OA	EAF	Beta	P	SE	N	Lead BA
12:20994540-21463812	SLCO1B1	rs4149056	Т	С	0.839	-0.25	1.10x10 ⁻¹⁶	0.03	4547	GDCA
10:53832549-53832549	PRKG1	rs146800892	Т	С	0.988	-0.96	3.30x10 ⁻⁰⁹	0.16	900	GCA
Sex-stratified										
Locus	Gene	SNP	EA	OA	Beta M	Beta F	P M	PF	N (M/F)	Lead BA
12:20994540-21463812	SLCO1B1	rs73079476	A	С	-0.51	-0.31	2.30x10 ⁻¹³	9.90x10 ⁻⁰⁷	820/1088	GDCA
10:53832549-53832549	PRKG1	rs117834398	T	G	-0.18	-0.79	1.80x10 ⁻⁰¹	8.30x10 ⁻¹¹	820/1088	GCA

Each locus is represented by the SNP with the strongest association in the region, according to the p-value rejecting the null hypothesis of no association with at least one of 18 bile acid traits. In all samples analysis, an association was considered significant if the p-value was lower than 3.57×10^{-9} , the genome-wide significance threshold Bonferroni-corrected for the number of independent bile acid traits. In sex-stratified analysis, an association was considered significant if the p-value was lower than 5×10^{-9} , the genome-wide significance threshold Bonferroni-corrected for the number of independent bile acid quantitative traits. The two SNPs in the *SLCO1B1* locus are in high LD (LD $r^2 = 0.97$), while the two SNPs in the *PRKG1* locus represent two distinct signals (LD $r^2 < 0.001$).

Locus - coded as 'chromosome: locus start—locus end' (GRCh37 human genome build); Gene - suggested candidate gene; SNP - variant with the strongest association in the locus; EA - SNP allele for which the effect estimate is reported; OA - other allele; EAF - frequency of the effect allele; Beta - effect estimate for the SNP and bile acid with the strongest association in the locus; SE - standard error of the effect estimate, P - p-value of the effect estimate (two-sided Wald test with one degree of freedom); N - sample size; Lead BA - bile acid with the strongest association to the reported SNP; M - male specific analysis; F - female specific analysis.

Sex-specific associations of bile acid serum levels

116

117

118

119 120

121

122

123

124 125

126 127

128

129

130 131

132

133 134

135

136

137

138 139 To investigate whether the genetic component influencing bile acid variation may differ between men and women, we performed sex-specific GWAS meta-analysis of the 14 quantitative (imputed) bile acid traits for ORCADES and CROATIA-Vis cohorts (female N=1088, male N=820) and discovered two sex-specific associations. The association of GDCA with rs73079476 from the SLCO1B1 locus was significant in male-only GWAS (beta = -0.51, p-value = 2.28×10^{-13}) (Table 1, Figure 2A). The signal for the same locus in female-only GWAS, while consistent in terms of directionality, has a smaller effect size than in male-only analysis (beta = -0.31) and does not reach the significance threshold (p-value = 9.86×10^{-7}). despite the slightly higher sample size (Figure 2). This suggests that the genetic effect of SLCO1B1 locus on the serum levels of GDCA is larger in men than women. We also identified a sex-specific association of GCA at the PRKG1 locus. In contrast to SLCO1B1, the sentinel SNP in PRKG1, rs117834398, has a larger effect in females than in males (female beta = -0.79, male beta = -0.18), and passed the significant threshold only in the female-specific analysis (female p-value = 8.26×10^{-11} , male p-value = 1.81×10^{-1}) (Table 1, Figure 2B). Interestingly, the sentinel SNPs at the *PRKG1* locus for the full meta-analysis and for the female-specific analysis are in linkage equilibrium ($r^2 < 0.01$) and represent two independent associations in that locus. Overall, none of the significant association identified in one sex was replicated in the other, suggesting that the genetic contribution to serum BA levels is likely to be different in males and females. We have identified 13 additional associations (p-value $\leq 5 \times 10^{-9}$). Bonferroni adjusted for the number of independent quantitative bile acid traits) that might have sex-specific effects (Supplementary Table 3, Supplementary Figure 1). However, given the low allele frequencies and allele counts in the two analysed cohorts, further analyses are required to replicate these associations.




Figure 2. Sex-specific associations. The effect of rs73079476 on chromosome 12 on GDCA bile acid is almost as twice strong in males compared to the effect in females (Panel A). The effect of rs117834398 on GCA bile acid is stronger in females than in males (Panel B). N – sample size, MAF – minor allele frequency, MAC – minor allele count, CI – confidence interval.

Link with complex traits and diseases

141

142 143

144

145

146

147

148

149

150

151 152

153

154

155

156 157

158

Next, we assessed whether variants associated with BA levels have been previously associated with any other biochemical traits and diseases. Using Phenoscanner^{16,17} we found that rs4149056, sentinel SNP in SLCO1B1 locus, and its proxies ($r^2 > 0.8$), were also associated with concentration of bilirubin, non-bile acid metabolites, mean corpuscular haemoglobin, sex hormone binding globulin and estrone conjugates, and various responses to drugs (i.e., statininduced myopathy, LDL-cholesterol response to simvastatin and methotrexate clearance in acute lymphoblastic leukaemia) (Supplementary Table 4). To obtain deeper insight into the causal relationship between BAs and diseases, we conducted bi-directional Mendelian Randomisation (MR) analysis. Using the sentinel SNPs associated with GLCA, GDCA and GCA (Table 1) as instrumental variables we tested whether genetically increased levels of BA influence levels or risk for 548 biochemical traits and diseases available in the IEU Open GWAS database¹⁸ (Supplementary Table 5). Levels of GLCA and GDCA were significantly

(p-value $< 0.05/(548x3) = 3.04 \times 10^{-5}$) associated with different biochemical measurements, such as levels of sex hormone-binding globulin, testosterone, triglycerides, vitamin D, alanine transaminase and galectin-3; with blood traits, such as mean corpuscular haemoglobin and mean corpuscular volume; and with diseases and their risk factors, such as daytime dozing and stroke (Supplementary Table 6). These MR tests were performed using the Wald ratio test utilising only a single instrument, thus the results of causal relationship between BAs and traits/diseases should be interpreted with caution. Yet our results suggest a possible overlap in genetic regulation, involving the SLCO1B1 locus. Next, to assess whether complex traits and disease could have an effect on bile acid levels, we performed reverse MR using 548 traits/diseases as exposure and bile acids as outcomes. We found no significant associations, suggesting that none of the tested diseases or complex traits have an effect on BA levels (Supplementary Table 7).

Exome-wide rare variant analysis of bile acids

159

160 161

162

163

164

165 166

167

168 169

170

171

172

173

174 175

176

177

178

179 180

181 182

183

184 185

186

187

188

To assess the contribution of low frequency and rare variants to the bile acid genetic architecture, we performed exome-wide gene-based tests across 18 bile acid traits in the ORCADES cohort (N = 1006) by testing the aggregated effect of rare (MAF <5%) predicted loss-of-function (pLoF) and non-synonymous missense variants. We identified significant association (p-value <1.79 x 10⁻⁷) of rare variants from 3 genes with 2 bile acid traits (quantitative CA and binary THDCA). For these associations, a significant p-value was reported by at least 2 of the 4 aggregation tests used. Rare variants significantly associated with quantitative bile acid trait CA are located in the OR1G1 gene, while those associated with binary bile acid trait THDCA are located in SART1 and SORCS2 genes (Table 2, Supplementary Table 8). We further identified significant association of rare variants from EPS8L1 gene with quantitative bile acid trait DCA and from EEF2K with binary bile acid trait THDCA (Supplementary Table 8). However, a significant p-value was reported by only one of the 4 aggregation tests used. Due to the lack of replication across aggregations tests, we considered these associations as not robust.

Table 2. Gene-based aggregation analysis results for bile acid traits in ORCADES cohort

BA	Trait type	Gene	MAF	Functional consequence	N variants	Aggregation test	P	AC
CA	Quantitative	OR1G1	<0.01	Missense variants	2	SKAT-O	1.67x10 ⁻⁸	17
THDCA	Binary	SORCS2	< 0.05	pLoF and missense variants	10	SMMAT-E	1.44x10 ⁻⁸	174
THDCA	Binary	SART1	<0.01	pLoF and missense variants	4	SKAT	1.19x10 ⁻⁷	25

BA- bile acid trait tested for rare variants association; Trait type - whether BA was analysed as a quantitative or binary trait; Gene gene for which variants were aggregated; MAF - upper bound for minor allele frequency of tested variants; Functional consequence predicted functional consequence for aggregated variants; N variants - number of variants in the mask; Aggregation test - rare-variants aggregation test reporting the lowest p-value out of 4 aggregation tests; P - p-value for the aggregation test; AC - cumulative allele count of all the variants in a mask. Bonferroni-corrected discovery p-value threshold was set to 1.79x10⁻⁷ (0.05/20,000 estimate of number of genes in the human genome/14 number of independent bile acids).

Discussion

189

190

191

192 193

194

195 196

197 198

199

200

201

202 203

204

205

206

207

208

209 210

211

212

213 214

215 216

217

218

219

220

221

222

223

Bile acids (BAs) are synthesised from cholesterol in the liver and then secreted into the small intestine to emulsify and promote absorption of lipid-soluble nutrients. BAs also act as hormone-like signalling molecules and have been linked to regulation of lipid and glucose metabolism, immunity, vitamin absorption, hepatobiliary diseases, inflammatory bowel disease and cancer. Despite the crucial role of BAs on whole-body physiology, their genetic architecture has not been extensively investigated in a large sample from the general population. In this study, we performed both pooled and sex-stratified genome-wide association meta-analysis of plasma levels of 18 bile acid compounds, including both primary and secondary forms, in 4923 European individuals.

We identified two secondary bile acids (GDCA and GLCA) significantly associated with a locus encompassing the SLCO1B1 gene. The encoded protein, OATP1B1 (organic anion transporting polypeptide 1B1), is a well-known human hepatocyte transporter mediating the uptake of various endogenous compounds such as bile salts, bilirubin glucuronides, thyroid hormones and steroid hormone metabolites, and also clinically frequently used drugs like statins, HIV protease inhibitors, and the anti-cancer agents irinotecan or methotrexate ^{19–23}. The sentinel SNP of the SLCO1B1 locus, rs4149056, is a missense variant (p.Val174Ala) which has been linked by previous GWA studies to blood concentration of several metabolites, including vitamin D²⁴, triglycerides²⁵ and bilirubin²⁶, a compound resulting from the breakdown of haem catabolism and excreted as a major component of bile. This same variant has also been associated with levels of sex hormone-binding globulin and testosterone²⁷. The knock-out of the gene in mice results in abnormal liver physiology and abnormal xenobiotic pharmacokinetic phenotypes (Open Targets²⁸). A rare variant from the *PRKG1* locus was significantly associated with levels of glycocholic acid (GCA). PRKG1 encodes a Protein Kinase CGMP-Dependent 1, a protein involved in signal transduction and a key mediator of the nitric oxide/cGMP. The sentinel variant in the region, rs146800892, only passes the MAF threshold (MAF > 0.01) in the CROATIA-Vis cohort, which is therefore the only cohort contributing to this association. Due to its demographic history and geographic position, CROATIA-Vis is a genetic isolate²⁹ so it is possible that this variant has increased in frequency compared to a general population³⁰. The mechanism of how the variation within this gene could relate to bile acid levels is unclear and would need to be further investigated.

In the sex-stratified GWAS meta-analysis, we observed sex-specific associations for the two identified loci. Levels of glycodeoxycholic acid (GDCA) are more strongly associated with the variant in SLCO1B1 in men than in women, while female levels of GCA are more strongly

224

225

226

227

228 229

230

231

232

233

234

235 236

237

238

239

240

241

242

243

244

245

246

247

248

249 250

251

252

253 254

255

256

257

258 259

260 261

262

263

affected by the variant in PRKG1 than male levels. Later, our Mendelian randomization analysis did not provide evidence that testosterone, oestradiol, sex hormone-binding globulin or other sex-related traits have causal effects on plasma BA levels. While this could be due to a lack of statistical power of our BA meta-analysis, we currently have no evidence to suggest an effect of sex-related hormones on BA levels mediated by genetics. We also detected associations with variants from the same gene, *PRKG1*, in the main, non-stratified analysis. However, the two associations (sex-specific and pooled) appear to be independent (LD r² <0.001). While the association from the pooled analysis might be either false positive or population-specific, the independent association from the sex-stratified analysis replicates well between two analysed cohorts (CROATIA-Vis and ORCADES).

After assaying common variants through GWAS, we performed exome-wide gene-based association tests in a subset of our samples (N = 1006), to investigate the genetic contribution of rare and low frequency (MAF <5%) coding variants (pLoF and missense) to bile acid levels. Overall, we identified associations with rare variants from 3 genes, OR1G1, SART1 and SORCS2. ORIG1 is an olfactory receptor gene, whose coded protein receptor interacts with odorant molecules in the nose to initiate a neuronal response triggering the perception of smell^{31,32}. In addition to the nasal level, the olfactory receptor coded by *ORIGI* is expressed also by enterochromaffin cells, specialised enteroendocrine cells of the gastrointestinal tract. Braun et al³³. determined that certain olfactory cues from spices and odorants, such as thymol, present in the luminal environment of the gut may stimulate serotonin release via olfactory receptors present in enterochromaffin cells. Between 90% and 95% of total body serotonin is in fact synthesised by enterochromaffin cells³⁴: serotonin controls gut motility and secretion and is implicated in pathologic conditions such as vomiting, diarrhoea, and irritable bowel syndrome³³. In mice, gut serotonin was shown to stimulate bile acid synthesis and secretion by the liver and gallbladder. Thus, release of serotonin in response to odorant cues increases bile acid turnover³⁵. The hypoxia-associated factor (HAF), encoded by SART1 gene and also known as SART1(800), is involved in proliferation and hypoxia-related signalling. The protein encoded by SORCS2 is a receptor for the precursor of nerve growth factor, up-regulation of which has been reported for several liver pathologies, such as hepatotoxin- induced fibrosis³⁶, ischemia-reperfusion injury³⁷, oxidative injury³⁸, cholestatic injury³⁹ and hepatocellular carcinoma^{36,40,41}. However, due to unavailability of exome sequencing data in other cohorts these associations were not replicated.

Recently, Chen et al. 42 have performed an association analysis on plasma and faecal levels of bile acids in 297 obese individuals. Their study revealed 27 associated loci, including genes involved in transport of GDP-fucose and zinc/manganese and zinc-finger-protein-related genes, mostly associated with bile acid levels in stool. In our study we analysed blood plasma in a much larger sample from a general population and discovered only two associated loci. Neither of genes identified in our study were reported in Chen et al, suggesting that genetic regulation of bile acids between stool and blood plasma or between obese and general populations might differ significantly.

264

265

266

267

268 269

270

271

272 273

274 275

276 277

278

279 280

281

282

283 284

285

286 287

288 289

290

291

292

293

294 295

296

297

298

299

300 301

302

303

304

We acknowledge several limitations in the present study. We found only a small percentage of BA variability to be affected by genetics, suggesting that a larger sample size is required to further describe BA genetic architecture. BAs are known to be largely influenced by environmental factors, such as sex and gut microbiota. Female sex and oestrogens are considered relevant regulators of BA production and composition^{43,44}. In pregnant women, high levels of circulating oestrogen are associated with development of cholestasis, characterised by increased serum bile acids, likely via oestrogen reducing the expression of BA receptor and transport proteins⁴⁵. Similarly, age-related differences in hormone levels influence the differential production of BAs in women⁴⁶. The relevant impact of sex on plasma BA levels was confirmed by the sex-stratified analysis, where the two significantly associated loci showed to be sex-specific. Similarly, species-composition of gut microbiota has a great impact on BAs levels, especially for secondary BAs that are a direct result of microbiome activity. A recent study describing the effect of gut microbiota on the human plasma metabolome reported that both primary BA cholic acid (CA) and secondary BA deoxycholic acid (DCA) show a high percentage of variance explained by the microbiota ($R^2 = 30\%$ and 36%, respectively), indicating a strong impact on BAs of the variation in microbiota composition⁴⁷. It is important to interpret our findings in the context of the tissue in which BA levels were measured, blood plasma. Bile acids are synthesised in the liver and secreted into the intestine, to be then reabsorbed into portal circulation and returned to the liver: plasma BA levels thus reflect the amount of BAs escaping extraction from the portal blood. Therefore, levels of BAs in plasma are likely to be influenced by genes other than those encoding the particular anabolic and catabolic enzymes, including those involved in hepatic function and dysfunction. In line with this, the major genetic contributor to blood BA levels in our study are variants from the SLCO1B1 gene, encoding the hepatocyte transporter OATP1B1 and important for flux of bile salts, bilirubin glucuronides and various hormone metabolites, rather than genes encoding key enzymes of primary BA synthesis, such as CYP7A1 and CYP7B1⁴⁸. Similarly, some of the genes with rare variants associations have been linked to liver diseases, such as liver cancer⁴⁹, and intrahepatic cholestasis of pregnancy⁵⁰.

In conclusion, we explored the genetic architecture of plasma bile acid levels, including both common and rare variants. By performing GWAS meta-analysis (N = 4923), we identified 2 significantly associated loci, mapping to the SLCO1B1 and PRKG1 genes. In the sex-specific GWAS meta-analysis we observed that variants in these genes have different impact on bile acid levels in men and women. To assess relationships between genetically increased levels of bile acids and risk for diseases we performed Mendelian randomisation, but did not find any bile acids affecting disease risk, nor the reverse, which however might be affected by the lack of statistical power. Using the gene-based aggregated tests and whole exome sequencing, we further identified rare pLoF and missense variants in 3 genes associated with BAs, OR1G1, SART1 and SORCS2, some of which are known to be involved in liver disease. Additional studies with larger sample sizes and of more diverse ancestry will be necessary to validate our findings, further unravel the genetic architecture of bile acid levels, and to understand their relationship with human diseases and complex traits.

Materials and methods

Phenotypic data

305

306

307

308

309 310

311

312

313

314

315

316

317

318

319 320

321

322 323

324

325

326

327

328

329

330 331

332

333

334

335

336 337

338

339 340

341

342

343

Bile acids quantification

Bile acid (BA) analysis was performed from plasma or serum (MICROS cohort) samples by liquid chromatography-tandem mass spectrometry (LC-MS/MS) as previously described⁵¹. The HPLC equipment consisted of a 1200 series binary pump (G1312B), a 1200 series isocratic pump (G1310A) and a degasser (G1379B) (Agilent, Waldbronn, Germany) connected to an HTC Pal autosampler (CTC Analytics, Zwingen, CH). A hybrid triple quadrupole linear ion trap mass spectrometer API 4000 O-Trap equipped with a Turbo V source ion spray operating in negative ESI mode was used for detection (Applied Biosystems, Darmstadt, Germany). High purity nitrogen was produced by a nitrogen generator NGM 22-LC/MS (cmc Instruments, Eschborn, Germany). Gradient chromatographic separation of BAs was performed on a 50 mm × 2.1 mm (i.d.) Macherey-Nagel NUCLEODUR C18 Gravity HPLC column, packed with 1.8 um particles equipped with a 0.5 µm pre-filter (Upchurch Scientific, Oak Harbor, WA, USA). The injection volume was 5 µL and the column oven temperature was set to 50 °C. Mobile phase A was methanol/water (1/1, v/v), mobile phase B was 100% methanol, both containing 0.1% ammonium hydroxide (25%) and 10 mmol/L ammonium acetate (pH 9). A gradient elution was performed with 100% A for 0.5 min, a linear increase to 50% A until 4.5 min, followed by 0% A from 4.6 until 5.5 min and re-equilibration from 5.6 to 6.5 min with 100% A. The flow rate was set to 500 µL/min. To minimize contamination of the mass spectrometer, the column flow was directed only from 1.0 to 5.0 min into the mass spectrometer using a diverter valve. Otherwise, methanol with a flowrate of 250 µL/min was delivered into the mass spectrometer. The turbo ion spray source was operated in the negative ion mode using the following settings: Ion spray voltage = -4500 V, ion source heater temperature = 450 °C, source gas 1 = 40 psi, source gas 2 = 35 psi and curtain gas setting = 20 psi. Analytes were monitored in the multiple reaction monitoring (MRM). Quadrupoles Q1 and Q3 were working at unit resolution. Calibration was achieved by the addition of BAs to EDTA-plasma/serum. A combined BA standard solution containing the indicated amounts (0.5 - 70.5 µmol/L) was placed in a 1.5 ml tube and excess solvent was evaporated under reduced pressure before adding EDTA-plasma/serum. Calibration curves were calculated by linear regression without weighting. Data analysis was performed with Analyst Software 1.4.2. (Applied Biosystems, Darmstadt, Germany). The data were exported to Excel spreadsheets and further processed by self-programmed Excel macros which sort the results, calculate the analyte/internal standard peak area ratios, generate calibration lines and calculate sample concentrations. For the calculation we selected the internal standard with analogous fragmentation and closest retention time to the respective BA species.

Pre-processing of bile acid traits

Prior to genetic analysis, bile acid traits were grouped into three groups based on the percentage of samples with below the limit of detection (<LOD) measurements: high <LOD group (> ~30% of all samples below LOD) and low <LOD group (< ~7% of all samples below LOD) (Supplementary Table 1). Accordingly, different phenotypic pre-processing and different analysis strategies were applied to the groups. Bile acids within a high <LOD were considered as binary traits: individuals were categorised based on whether their bile acid levels were effectively measured (category 1) or were below the LOD (category 0). Bile acid traits belonging to this group were THDCA, TUDCA, TCA and GHDCA. All other bile acids were considered as quantitative traits and were log₁₀-transformed. However, to increase the sample size, in addition to a complete-case analysis (considering as missing all samples with <LOD), we also imputed <LOD measurements. For each bile acid, imputation of <LOD measurements was performed by fitting a truncated normal distribution, with mean and standard deviation of the effectively measured raw data, truncated (as an upper bound) to the lowest measured value for the given bile acid. To do so, we used the "rtnorm" function from the MCMCglmm R package⁵². After imputation, measurements were log₁₀-transformed.

Genome-wide association analysis

344

345

346

347

348 349

350

351 352

353

354

355

356 357

358

359

360

361

362

363

364

365 366

367

368 369

370 371

372

373 374

375

376 377

378

379

380 381

382

383

Genome-wide association studies (GWAS) were performed in 5 cohorts of European descent, CROATIA-Vis (N=971), ORCADES (Orkney Complex Disease Study) (N=1019), NSPHS (Northern Sweden Population Health Study) (N=718), MICROS (Micro-Isolates in South Tyrol) (N=1336) and ERF (Erasmus Rucphen Family Study) (N=879), for a combined sample size of 4923. Specific sample size for each bile acid molecule, in both meta-analysis and single cohort GWAS, can be found in Supplementary Table 10. Bile acid traits were adjusted for age, sex, batch, population structure/cryptic relatedness by including population principal components or applying linear mixed models and using a kinship matrix estimated from genotyped data. Within each cohort, residuals of covariate and population structure/relatedness correction were tested for association with Haplotype Reference Consortium (HRC)⁵³ imputed SNP dosages or SNP genotypes from whole genome sequencing, applying an additive genetic model of association. Details of cohorts, individual-level pre-imputation QC, GWAS software and parameters specific for each cohort can be seen in Supplementary Table 11 Single-cohort summary statistics were filtered for minor allele frequency (MAF) > 0.01. The genomic control inflation factor (λ_{GC}) was calculated for each bile acid trait. Cohort-level λ_{GC} overall ranged from 0.9 to 1.1 for quantitative bile acid traits, both imputed and not, suggesting little residual influence of population stratification and family structure (Supplementary Table 12). In a few cases, ERF cohort reported somewhat deflated λ_{GC} (GCDCA at 0.884 and GLCA at 0.899). On the other hand, there was considerable inflation for binary bile acid in the case of NSPHS (Supplementary Table 12), with values of λ_{GC} above 1.1, suggesting that population structure/cryptic relatedness was not fully controlled for these traits in the NSPHS cohort.

Meta-analysis

Prior to meta-analysis, cohort-level GWAS were quality controlled using the EasyQC software package, following the protocol described in Winkler et al.⁵⁴ Cohort-level results were corrected for the genomic control inflation factor, then pooled and analysed with METAL v2011-03-25 software⁵⁵, applying the fixed-effect inverse-variance method. The mean genomic control inflation factor after the meta-analysis was 0.991 (range 0.938 – 1.009), suggesting that the confounding effects of the family structure were correctly accounted for (Supplementary Table 12). The standard genome-wide significance threshold was Bonferroni corrected for the number of independent bile acid traits, calculated as $14 (5x10^{-8}/14 = 3.57x10^{-9})$. The number of independent bile acid traits was estimated as the sum of the number of binary traits (4) and the number of principal components that jointly explained 99% of the total variance of log₁₀transformed quantitative traits in each cohort (10) (Supplementary Table 13).

Sex-stratified GWAS meta-analysis

384

385

386

387

388 389

390

391

392

393

394

395

396

397 398

399

400

401

402

403

404

405

406 407

408 409

410 411

412

413

414

415

416

417

418

419

420

421

422

To identify possible differences in the genetic contribution to bile acid variability between men and women, we performed sex-specific GWAS of the 14 quantitative bile acid traits for ORCADES and CROATIA-Vis cohorts. Given that for the sex-stratified GWAS we implicitly halve our sample size, we performed these analyses only on the imputed bile acid traits. The same analysis steps and procedures already described for the full meta-analysis were applied. Bile acid traits were adjusted for age, sex and batch as fixed effects, and relatedness (estimated as the kinship matrix calculated from genotyped data) as a random effect in a linear mixed model, calculated using the 'polygenic' function from the GenABEL R package⁵⁶. Residuals of covariate and relatedness correction were tested for association with HRC-imputed⁵³ SNP dosages using the RegScan v0.5 software⁵⁷, applying an additive genetic model of association. Prior to meta-analysis, SNPs having a difference in allele frequency between the two cohorts higher than ±0.3 or a minor allele count (MAC) lower or equal to 6 were filtered out. Cohortlevel GWAS were corrected for genomic control inflation factor and then meta-analysed $(N = 820 \text{ for male and } N = 1088 \text{ for female individuals}) \text{ using METAL } v2011-03-25 \text{ software}^{55}$, applying the fixed-effect inverse-variance method. The mean λ_{GC} was 0.993 (range 0.978– 1.011) for male-specific meta-analysis and 0.996 (range 0.984–1.003) for female-specific meta-analysis. The Bonferroni-corrected significance threshold applied is 5×10^{-9} .

Phenoscanner and Mendelian Randomisation

To assess link between bile acids and diseases we explored the overlap of SNPs associated with BAs with complex human traits by using PhenoScanner v1.1 database^{16,17}, taking into account significant genetic association ($p < 5 \times 10^{-9}$) at the same or strongly (LD r2 > 0.8) linked SNPs in populations of European ancestry. We then performed bi-directional Mendelian Randomisation (MR) to investigate the effect of 548 complex traits and diseases available in the IEU Open GWAS database¹⁸ (manually curated list of studies from identifiers ebi-a, ieu-a, ieu-b and ukb-a; the complete list reported in the Supplementary Table 5) on BA levels, and

vice-versa. The set of genome-wide significant, LD clumped SNPs used as instruments for complex traits/diseases was extracted from the selected studies by using the "extract instruments" function from the TwoSampleMR 0.5.6 R package⁵⁸. Similarly, sentinel SNPs from BAs meta-analysis (Supplementary Table 2) were selected as instruments. MR tests were performed by using fixed effects inverse variance-weighted (IVW) in case of multiple instruments or Wald Ratio method in case of a single instrument, as implemented in the TwoSampleMR 0.5.6 R package⁵⁸. Multiple testing correction was controlled for using either the Bonferroni correction or false discovery rate (FDR).

Whole-exome sequencing data

Exome sequencing

423

424

425

426

427 428

429

430

431

432

433

434

435 436

437

438

439

440

441

442

443

444

445 446

447

448

449 450

451

452

453

454

455

456

457

458

459

460

The "Goldilocks" exome sequence data for ORCADES cohort was prepared at the Regeneron Genetics Center, following the protocol detailed in Van Hout et al.⁵⁹ for the UK Biobank whole-exome sequencing project. In summary, sequencing was performed using S2 flow cells on the Illumina NovaSeq 6000 platform with multiplexed samples. DNAnexus platform⁶⁰ was used for processing raw sequencing data. The files were converted to FASTO format and aligned using the BWA-mem⁶¹ to GRCh38 genome reference. The Picard tool⁶² was used for identifying and flagging duplicated reads, followed by calling the genotypes for each individual sample using the WeCall variant caller⁶³. During quality control, 33 samples genetically identified as duplicates, 3 samples showing disagreement between genetically determined and reported sex, 4 samples with high rates of heterozygosity or contamination, 2 samples having low sequence coverage (less than 80% of targeted bases achieving 20X coverage) and 1 being discordant with genotyping chip were excluded. Finally, the "Goldilocks" dataset was generated by (i) filtering out genotypes with read depth lower than 7 reads, (ii) keeping variants having at least one heterozygous variant genotype with allele balance ratio greater than or equal to 15% (AB \geq 0.15) or at least one homozygous variant genotype, and (iii) filtering out variants with more than 10% of missingness and HWE p<10⁻⁶. Overall, a total of 2,090 ORCADES (820 male and 1,270 female) participants passed all exome sequence and genotype quality control thresholds. A pVCF file containing all samples passing quality control was then created using the GLnexus joint genotyping tool⁶⁴.

Variant annotation

Exome sequencing variants were annotated as described in Van Hout, et al. 59 Briefly, they were annotated with the most severe consequence across all protein-coding transcripts using SnpEff⁶⁵. Gene regions were defined based on Ensembl release 85⁶⁶. Predicted loss-of function (pLoF) variants were defined as variants annotated as start lost, stop gained/lost, splice donor/acceptor and frameshift. The deleteriousness of missense variants was based on dbNSFP 3.2^{67,68} and assessed using the following algorithms: (1) SIFT⁶⁹: "D" (Damaging), (2)

- 461 Polyphen2 HDIV: "D" (Damaging) or "P" (Possibly damaging), (3) Polyphen2 HVAR⁷⁰: "D"
- (Damaging) or "P" (Possibly damaging), (4) LRT⁷¹: "D" (Deleterious) and (5) 462
- MutationTaster⁷²: "A" (Disease causing automatic) or "D" (Disease causing). If not predicted 463
- as deleterious by any of the algorithms the missense variants were considered "likely benign". 464
- "possibly deleterious" if predicted as deleterious by at least one of the algorithms and "likely 465
- 466 deleterious" if predicted as deleterious by all five algorithms.

Exome-wide gene-based aggregation analysis of rare variants

469 Generation of gene masks

467

468

477

478

- 470 For each gene, the variants were grouped into four categories (masks), based on severity of
- 471 their functional consequence. The first mask (mask 1) included only pLoF variants. Masks 3
- 472 and 4 included both pLoF and variants predicted to be deleterious, by 5/5 algorithms (mask 3)
- or by at least one algorithm (mask 4). The most permissive mask (mask 2) included pLoF and 473
- 474 all missense variants. These masks were then further split by the frequencies of the minor allele
- 475 $(MAF \le 5\%, e.g. mask1 maf5; and MAF \le 1\%, e.g. mask1_maf1)$, resulting in up to 8 burden
- 476 tests for each gene (Supplementary Table 9).

ORCADES gene-based aggregation analysis

- We performed variant Set Mixed Model Association Tests (SMMAT)⁷³ on the 18 bile acid 479
- 480 traits from ORCADES cohort, quantified and pre-processed as previously described, fitting a
- 481 GLMM adjusting for age, sex, batch, and familial or cryptic relatedness by kinship matrix. The
- kinship matrix was estimated from the genotyped data using the 'ibs' function from GenABEL 482
- R package⁵⁶. The SMMAT framework includes 4 variant aggregate tests: burden test, sequence 483
- kernel association test (SKAT), SKAT-O and SMMAT-E, a hybrid test combining the burden 484
- 485 test and SKAT. The 4 variant aggregate tests were performed on 8 different pools of genetic
- 486 variants, called "masks", each one including a different set of variants based on both MAF and
- predicted consequence of variants (e.g., loss of function and missense) (Supplementary Table 487
- 9), as described above. Discovery significance threshold was Bonferroni corrected for the 488
- 489 rough estimate of the number of genes in the human genome, 20,000, and the number of
- independent bile acid traits, 14, calculated as previously described $(0.05/20000/14 = 1.79 \times 10^{-1})$ 490
- 491 7). A gene association was considered significant if it passed the above reported Bonferroni
- corrected significance threshold in at least two of the 4 performed variant aggregate tests and 492
- 493 if the cumulative allele count of the variants included in the gene was equal or higher than 10.

Code availability

494

495 496

497

498

499

500 501

502 503

504 505

506 507

508 509 We used publicly available software tools for all analyses. These software tools are listed in the main text and in the Methods.

Data availability

The full summary statistics from GWAS meta-analysis of bile acids will be uploaded to the University of Edinburgh Datashare repository and to GWAS catalog upon manuscript acceptance. There is neither Research Ethics Committee approval, nor consent from individual participants, to permit open release of the individual level research data underlying this study. The datasets analysed during the current study are therefore not publicly available. Instead, the research data and/or DNA samples for the ORCADES study are available from accessQTL@ed.ac.uk on reasonable request, following approval by the QTL Data Access Committee and in line with the consent given by participants. Each approved project is subject to a data or materials transfer agreement (D/MTA) or commercial contract. The summary statistics for complex traits and diseases (full list reported in Supplementary Table 5) are available in the IEU Open GWAS database https://gwas.mrcieu.ac.uk/.

References

510

- 511 1. Lorbek, G., Lewinska, M. & Rozman, D. Cytochrome P450s in the synthesis of
- 512 cholesterol and bile acids – from mouse models to human diseases. FEBS J. 279, 513 1516–1533 (2012).
- 514 2. Chiang, J. Y. L. Bile Acid Metabolism and Signaling. Compr. Physiol. 3, 1191–1212 515 (2013).
- 516 3. Thomas, C., Pellicciari, R., Pruzanski, M., Auwerx, J. & Schoonjans, K. Targeting 517 bile-acid signalling for metabolic diseases. Nature Reviews Drug Discovery 7, 678– 518 693 (2008).
- 519 4. de Aguiar Vallim, T. Q., Tarling, E. J. & Edwards, P. A. Pleiotropic roles of bile acids 520 in metabolism. Cell Metab 17, 657–669 (2013).
- 521 5. Perino, A., Demagny, H., Velazquez-Villegas, L. & Schoonjans, K. Molecular 522 Physiology of Bile Acid Signaling in Health, Disease, and Aging. *Physiol Rev* 101, 523 683-731 (2021).
- 524 6. Fiorucci, S. et al. Bile Acid Signaling in Inflammatory Bowel Diseases. Dig Dis Sci 525 **66**, 674–693 (2021).
- 526 7. Rezen, T. et al. The role of bile acids in carcinogenesis. Cell Mol Life Sci 79, 243 527 (2022).
- 528 Danic, M. et al. Pharmacological Applications of Bile Acids and Their Derivatives in 8. 529 the Treatment of Metabolic Syndrome. Front Pharmacol 9, 1382 (2018).
- 530 9. Stojančević, M., Pavlović, N., Goločorbin-Kon, S. & Mikov, M. Application of bile 531 acids in drug formulation and delivery. Front. Life Sci. 7, 112–122
- 532 10. Surendran, P. et al. Rare and common genetic determinants of metabolic individuality 533 and their effects on human health. Nat Med 28, 2321–2332 (2022).
- 534 Bomba, L. et al. Whole-exome sequencing identifies rare genetic variants associated 11. 535 with human plasma metabolites. Am. J. Hum. Genet. 109, 1038–1054 (2022).
- 536 12. Demirkan, A. et al. Insight in genome-wide association of metabolite quantitative traits 537 by exome sequence analyses. PLoS Genet 11, e1004835 (2015).
- 538 13. Kettunen, J. et al. Genome-wide study for circulating metabolites identifies 62 loci and 539 reveals novel systemic effects of LPA. Nat. Commun. 7, 1–9 (2016).
- 540 14. Lotta, L. A. et al. A cross-platform approach identifies genetic regulators of human 541 metabolism and health. *Nat. Genet.* **53**, 54–64 (2021).
- 542 15. Shin, S. Y. et al. An atlas of genetic influences on human blood metabolites. Nat. 543 Genet. 46, 543-550 (2014).
- 544 16. Staley, J. R. et al. PhenoScanner: A database of human genotype-phenotype associations. *Bioinformatics* **32**, 3207–3209 (2016). 545
- 546 17. Kamat, M. A. et al. PhenoScanner V2: an expanded tool for searching human 547 genotype–phenotype associations. *Bioinformatics* **35**, 4851–4853 (2019).
- 548 18. Elsworth, B. et al. The MRC IEU OpenGWAS data infrastructure. bioRxiv 549 2020.08.10.244293 (2020). doi:10.1101/2020.08.10.244293
- 550 19. Hagenbuch, B. & Meier, P. J. Organic anion transporting polypeptides of the OATP/ 551 SLC21 family: phylogenetic classification as OATP/ SLCO superfamily, new
- 552 nomenclature and molecular/functional properties. Pflugers Arch 447, 653–665 553 (2004).
- 554 20. Ho, R. H. & Kim, R. B. Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther 78, 260–277 (2005). 555
- 556 21. International Transporter, C. et al. Membrane transporters in drug development. Nat 557 Rev Drug Discov 9, 215–236 (2010).
- Niemi, M., Pasanen, M. K. & Neuvonen, P. J. Organic anion transporting polypeptide 558 22.

- 559 1B1: a genetically polymorphic transporter of major importance for hepatic drug 560 uptake. Pharmacol Rev 63, 157–181 (2011).
- 561 23. Nies, A. T., Schwab, M. & Keppler, D. Interplay of conjugating enzymes with OATP 562 uptake transporters and ABCC/MRP efflux pumps in the elimination of drugs. Expert 563 *Opin Drug Metab Toxicol* **4**, 545–568 (2008).
- 564 Revez, J. A. et al. Genome-wide association study identifies 143 loci associated with 24. 565 25 hydroxyvitamin D concentration. *Nat Commun* **11**, 1647 (2020).
- 566 25. Willer, C. J. et al. Discovery and refinement of loci associated with lipid levels. Nat. 567 Genet. 45, 1274–1285 (2013).
- 568 Johnson, A. D. et al. Genome-wide association meta-analysis for total serum bilirubin 26. levels. Hum. Mol. Genet. 18, 2700–2710 (2009). 569
- 570 27. Ruth, K. S. et al. Using human genetics to understand the disease impacts of 571 testosterone in men and women. Nat Med 26, 252-258 (2020).
- 572 28. Ochoa, D. et al. Open Targets Platform: supporting systematic drug-target 573 identification and prioritisation. *Nucleic Acids Res* **49**, D1302–D1310 (2021).
- 574 29. Vitart, V. et al. 3000 years of solitude: extreme differentiation in the island isolates of 575 Dalmatia, Croatia. Eur. J. Hum. Genet. 14, 478–487 (2006).
- Zuk, O. et al. Searching for missing heritability: Designing rare variant association 576 30. 577 studies. (2014). doi:10.1073/pnas.1322563111
- 578 31. Koh, M. Y., Lemos Jr., R., Liu, X. & Powis, G. The hypoxia-associated factor 579 switches cells from HIF-1alpha- to HIF-2alpha-dependent signaling promoting stem 580 cell characteristics, aggressive tumor growth and invasion. Cancer Res 71, 4015–4027 581 (2011).
- 582 32. Semenza, G. L. Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. 583 Crit Rev Biochem Mol Biol 35, 71–103 (2000).
- 584 33. Braun, T., Voland, P., Kunz, L., Prinz, C. & Gratzl, M. Enterochromaffin cells of the 585 human gut: sensors for spices and odorants. Gastroenterology 132, 1890–1901 (2007).
- 586 34. Erspamer, V. Pharmacology of indole-alkylamines. *Pharmacol Rev* 6, 425–487 (1954).
- 587 Watanabe, H. et al. Peripheral serotonin enhances lipid metabolism by accelerating 35. 588 bile acid turnover. *Endocrinology* **151**, 4776–4786 (2010).
- 589 Oakley, F. et al. Hepatocytes express nerve growth factor during liver injury: evidence 36. 590 for paracrine regulation of hepatic stellate cell apoptosis. Am J Pathol 163, 1849–1858 (2003).591
- 592 Ohkubo, T. et al. Early induction of nerve growth factor-induced genes after liver 37. 593 resection-reperfusion injury. J Hepatol 36, 210–217 (2002).
- 594 38. Valdovinos-Flores, C. & Gonsebatt, M. E. Nerve growth factor exhibits an antioxidant 595 and an autocrine activity in mouse liver that is modulated by buthionine sulfoximine, 596 arsenic, and acetaminophen. Free Radic Res 47, 404–412 (2013).
- 597 39. Gigliozzi, A. et al. Nerve growth factor modulates the proliferative capacity of the 598 intrahepatic biliary epithelium in experimental cholestasis. Gastroenterology 127, 599 1198–1209 (2004).
- 600 40. Rasi, G. et al. Nerve growth factor involvement in liver cirrhosis and hepatocellular 601 carcinoma. World J Gastroenterol 13, 4986–4995 (2007).
- 602 Tokusashi, Y. et al. Expression of NGF in hepatocellular carcinoma cells with its 41. 603 receptors in non-tumor cell components. Int J Cancer 114, 39–45 (2005).
- 604 42. Chen, L. et al. Genetic and Microbial Associations to Plasma and Fecal Bile Acids in 605 Obesity Relate to Plasma Lipids and Liver Fat Content. Cell Rep. 33, 108212 (2020).
- 606 43. Phelps, T., Snyder, E., Rodriguez, E., Child, H. & Harvey, P. The influence of 607
- biological sex and sex hormones on bile acid synthesis and cholesterol homeostasis. Biol. Sex Differ. 2019 101 10, 1–12 (2019). 608

- 609 Li-Hawkins, J. et al. Cholic acid mediates negative feedback regulation of bile acid 44. 610 synthesis in mice. J Clin Invest 110, 1191–1200 (2002).
- 611 45. Abu-Hayyeh, S. et al. Intrahepatic cholestasis of pregnancy levels of sulfated 612 progesterone metabolites inhibit farnesoid X receptor resulting in a cholestatic 613 phenotype. *Hepatology* **57**, 716–726 (2013).
- 614 Frommherz, L. et al. Age-Related Changes of Plasma Bile Acid Concentrations in 46. 615 Healthy Adults--Results from the Cross-Sectional KarMeN Study. PLoS One 11, 616 e0153959 (2016).
- 617 47. Dekkers, K. F. et al. An online atlas of human plasma metabolite signatures of gut 618 microbiome composition. *Nat. Commun.* 2022 131 13, 1–12 (2022).
- 619 48. Russell, D. W. The Enzymes, Regulation, and Genetics of Bile Acid Synthesis. Annu. Rev. Biochem. 72, 137–174 (2003). 620
- 621 49. Thomas, C. E. et al. Association between Pre-Diagnostic Serum Bile Acids and 622 Hepatocellular Carcinoma: The Singapore Chinese Health Study. Cancers (Basel) 13, 623 (2021).
- Manzotti, C., Casazza, G., Stimac, T., Nikolova, D. & Gluud, C. Total serum bile acids 624 50. 625 or serum bile acid profile, or both, for the diagnosis of intrahepatic cholestasis of 626 pregnancy. Cochrane Database Syst Rev 7, CD012546 (2019).
- 627 51. Scherer, M., Gnewuch, C., Schmitz, G. & Liebisch, G. Rapid quantification of bile 628 acids and their conjugates in serum by liquid chromatography-tandem mass spectrometry. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 877, 3920-3925 629 630 (2009).
- 631 52. Hadfield, J. D. MCMC Methods for Multi-Response Generalized Linear Mixed 632 Models: TheMCMCglmmRPackage. J. Stat. Softw. 33, (2010).
- 633 McCarthy, S. et al. A reference panel of 64,976 haplotypes for genotype imputation. 53. 634 Nat. Genet. 48, 1279-1283 (2016).
- Winkler, T. W. et al. Quality control and conduct of genome-wide association meta-635 54. analyses. Nat. Protoc. 9, 1192–1212 (2014). 636
- 637 Willer, C. J., Li, Y. & Abecasis, G. R. METAL: Fast and efficient meta-analysis of 55. 638 genomewide association scans. *Bioinformatics* **26**, 2190–2191 (2010).
- 639 Karssen, L. C., van Duijn, C. M. & Aulchenko, Y. S. The GenABEL Project for 56. 640 statistical genomics. F1000Research 5, (2016).
- 641 Haller, T., Kals, M., Esko, T., Mägi, R. & Fischer, K. RegScan: A GWAS tool for 57. 642 quick estimation of allele effects on continuous traits and their combinations. Brief. 643 Bioinform. 16, 39–44 (2013).
- 644 58. Hemani, G. et al. The MR-base platform supports systematic causal inference across 645 the human phenome. *Elife* 7, (2018).
- 646 59. Van Hout, C. V et al. Exome sequencing and characterization of 49,960 individuals in 647 the UK Biobank. *Nature* **586**, 749–756 (2020).
- Reid, J. G. et al. Launching genomics into the cloud: deployment of Mercury, a next 648 60. 649 generation sequence analysis pipeline. BMC Bioinformatics 15, 30 (2014).
- 650 61. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler 651 transform. *Bioinformatics* **25**, 1754–1760 (2009).
- 652 "Picard Toolkit." 2019. Broad Institute, GitHub Repository. 62. https://broadinstitute.github.io/picard/; Broad Institute. 653
- 654 PLC, G. weCall. (2018). 63.
- 655 Lin, M. F. et al. GLnexus: joint variant calling for large cohort sequencing. bioRxiv 64. 656 (2018). doi:10.1101/343970
- Cingolani, P. et al. A program for annotating and predicting the effects of single 657 65. nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster 658

659 strain w1118; iso-2; iso-3. Fly 6, 80–92 (2012).

679

- 660 Zerbino, D. R. et al. Ensembl 2018. Nucleic Acids Res. 46, D754–D761 (2018). 66.
- Liu, X., Wu, C., Li, C. & Boerwinkle, E. dbNSFP v3.0: A One-Stop Database of 661 67. 662 Functional Predictions and Annotations for Human Nonsynonymous and Splice-Site 663 SNVs. *Hum Mutat* **37**, 235–241 (2016).
- Liu, X., Jian, X. & Boerwinkle, E. dbNSFP: a lightweight database of human 664 68. nonsynonymous SNPs and their functional predictions. Hum Mutat 32, 894–899 665 666 (2011).
- 667 69. Vaser, R., Adusumalli, S., Leng, S. N., Sikic, M. & Ng, P. C. SIFT missense predictions for genomes. Nat Protoc 11, 1–9 (2016). 668
- 669 70. Adzhubei, I. A. et al. A method and server for predicting damaging missense 670 mutations. Nat. Methods 7, 248–249 (2010).
- 671 71. Chun, S. & Fay, J. C. Identification of deleterious mutations within three human 672 genomes. Genome Res 19, 1553–1561 (2009).
- Schwarz, J. M., Rodelsperger, C., Schuelke, M. & Seelow, D. MutationTaster 673 72. 674 evaluates disease-causing potential of sequence alterations. Nat Methods 7, 575–576 675 (2010).
- 676 73. Chen, H. et al. Efficient Variant Set Mixed Model Association Tests for Continuous and Binary Traits in Large-Scale Whole-Genome Sequencing Studies. Am. J. Hum. 677 678 Genet. 104, 260-274 (2019).

Acknowledgments

680

681

682

683

684

685

686 687

688

689

690

691 692

693

694

695

696 697

698

699 700

701

702 703

704

705

706

707 708

709

710

711

712

713

714

715

716 717

718

719

720

721

722

The Orkney Complex Disease Study (ORCADES) was supported by the Chief Scientist Office of the Scottish Government (CZB/4/276, CZB/4/710), a Royal Society URF to J.F.W., the MRC Human Genetics Unit quinquennial programme "QTL in Health and Disease", Arthritis Research UK and the European Union framework program 6 EUROSPAN project (contract no. LSHG-CT-2006-018947). DNA extractions were performed at the Edinburgh Clinical Research Facility, University of Edinburgh. We would like to acknowledge the invaluable contributions of the research nurses in Orkney, the administrative team in Edinburgh and the people of Orkney. For the purpose of open access, the author has applied a Creative Commons Attribution (CC BY) licence to any Author Accepted Manuscript version arising from this submission. The CROATIA-VIS study in the Croatian island of Vis was supported through the grants from the Medical Research Council UK and Ministry of Science, Education and Sport of the Republic of Croatia (number 108-1080315-0302). The authors collectively thank a large number of individuals for their individual help in organising, planning and carrying out the field work related to the project and data management: Professor Pavao Rudan and the staff of the Institute for Anthropological Research in Zagreb, Croatia (organisation of the field work, anthropometric and physiological measurements, and DNA extraction); Professor Ariana Vorko-Jovic and the staff and medical students of the Andrija Stampar School of Public Health of the Faculty of Medicine, University of Zagreb, Croatia (questionnaires, genealogical reconstruction and data entry); Dr Branka Salzer from the biochemistry lab "Salzer", Croatia (measurements of biochemical traits); local general practitioners and nurses (recruitment and communication with the study population); and the employees of several other Croatian institutions who participated in the field work, including but not limited to the University of Rijeka and Split, Croatia; Croatian Institute of Public Health; Institutes of Public Health in Split and Dubrovnik, Croatia. SNP Genotyping of the Vis samples was carried out by the Genetics Core Laboratory at the Wellcome Trust Clinical Research Facility, WGH, Edinburgh. The MICROS (Micro-Isolates in South Tyrol) study is part of the genomic health care program 'GenNova' and was carried out in three villages of the Val Venosta on the populations of Stelvio, Vallelunga and Martello. We thank the primary care practitioners Raffaela Stocker, Stefan Waldner, Toni Pizzecco, Josef Plangger, Ugo Marcadent and the personnel of the Hospital of Silandro (Department of Laboratory Medicine) for their participation and collaboration in the research project. In South Tyrol, the study was supported by the Ministry of Health and Department of Educational Assistance, University and Research of the Autonomous Province of Bolzano and the South Tyrolean Sparkasse Foundation. The Northern Swedish Population Health Study (NSPHS) was funded by the Swedish Medical Research Council (project number K2007-66X-20270-01-3), and the Foundation for Strategic Research (SSF). The NSPHS as part of EUROSPAN (European Special Populations Research Network) was also supported by European Commission FP6 STRP grant number 01947 (LSHGCT-2006-01947). This work was also supported by the Swedish Society for Medical Research (ÅJ). The authors are grateful for the contribution of district nurse Svea Hennix for data collection and Inger Jonasson for logistics and coordination of the health survey. Finally, the authors thank all the community participants for their interest and willingness to contribute to the study. The Erasmus Rucphen Family (ERF) study was supported by grants from The Netherlands

723 Organisation for Scientific Research (NWO), Erasmus MC, the Centre for Medical Systems 724 Biology (CMSB) and the European Community's Seventh Framework Programme (FP7/2007-2013), ENGAGE Consortium, grant agreement HEALTH-F4-2007- 201413. We are grateful 725 to all general practitioners for their contributions. Cornelia van Dujin and Ben Oostra for 726 727 setting-up the ERF study, Petra Veraart for sorting out the genealogy records, Jeannette 728 Vergeer and Peter Snijders for help in retrieving the materials needed to analyse data. We 729 acknowledge support from the European Union's Horizon 2020 research and innovation 730 programme IMforFUTURE (A.L.: H2020-MSCA-ITN/721815); the RCUK Innovation 731 Fellowship from the National Productivity Investment Fund (L.K.: MR/R026408/1) and the MRC Human Genetics Unit programme grant, 'QTL in Health and Disease' (J.F.W. and C.H.: 732 733 MC UU 00007/10).

Ethics

734

735

745

746

747

748

749 750

751

752

753

754

755 756

757

758

759 760

761

736 All studies were approved by local research ethics committees and all participants have given written informed consent. The ORCADES study was approved by the NHS Orkney Research 737 738 Ethics Committee and the North of Scotland REC. The CROATIA-Vis study was approved by 739 the ethics committee of the medical faculty in Zagreb and the Multi-Centre Research Ethics Committee for Scotland. The Northern Swedish Population Health Study (NSPHS) was 740 741 approved by the local ethics committee at the University of Uppsala (Regionala 742 Etikprövningsnämnden, Uppsala). The MICROS study was approved by the ethical committee 743 of the Autonomous Province of Bolzano, Italy. The ERF study was approved by the Erasmus 744 institutional medical-ethics committee in Rotterdam, The Netherlands.

Author contributions

A.L.: Data analysis and interpretation, visualisation, writing—original draft preparation, writing—review and editing. D.G.-S.: Data analysis, writing—review and editing. Å.J.: Data analysis. S.A.: Data analysis. G.L.: Quantification of bile acids, writing—original draft preparation. C.G.: Quantification of bile acids, writing—original draft preparation. G.T.: preparation, quality control and annotation of whole-exome sequencing data. A.R.S.: Funding, writing—review and editing. A.A.H.: Genomic and demographic data provider for MICROS cohort. P.P.: Funding, genomic and demographic data provider for MICROS cohort. C.P.: genomic and demographic data provider for MICROS cohort. H.C. Funding. O.P.: Genomic and demographic data provider for CROATIA-Vis cohort. C.H.: Funding, genomic and demographic data provider for CROATIA-Vis cohort. N.P.: supervision and data interpretation for bile acid pre-processing and imputation. M.G.: Genomic and demographic data provider for ERF cohort, writing—review and editing. U.G.: Funding, genomic and demographic data provider for NSPHS cohort. C.F.: Genomic and demographic data provider for MICROS cohort. J.F.W.: Funding, conceptualisation, genomic and demographic data provider for ORCADES cohort, supervision, data interpretation, writing—original draft preparation,

writing—review and editing. L.K.: Conceptualisation, supervision, data interpretation, writing—original draft preparation, writing—review and editing.

Competing interests

762

763

764

765

766

767 768

769

G.T. and A.R.S. are full-time employees of Regeneron Genetics Center and receive salary, stock and stock options as compensation. L.K. is an employee of Humanity Inc., a company developing direct-to-consumer measures of biological ageing. All other authors declare no competing interests.